CoChat

Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma

Open access
Richardson, Paul G., Trudel, Suzanne, Popat, Rakesh, Mateos, María-Victoria, Vangsted, Annette J., Ramasamy, Karthik, Martinez-Lopez, Joaquín, Quach, Hang, Orlowski, Robert Z., Arnao, Mario, Lonial, Sagar, Karanes, Chatchada, Pawlyn, Charlotte, Kim, Kihyun, Oriol, Albert, Berdeja, Jesus G., Rodríguez Otero, Paula, Casas-Avilés, Ignacio, Spirli, Alessia, Poon, Jennifer, Li, Shaoyi, Gong, Jing, Wong, Lilly, Lamba, Manisha, Pierce, Daniel W., Amatangelo, Michael, Peluso, Teresa, Maciag, Paulo, Katz, Jessica, Pourdehnad, Michael, Bahlis, Nizar J. · 2023 · New England Journal of Medicine
Cited by 102

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Despite recent progress, multiple myeloma remains incurable. Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide. METHODS: In this phase 1-2 study, we administered oral mezigdomide in combination with dexamethasone to patients with relapsed and refractory myeloma. The primary objectives of phase 1 (dose-escalation cohort) were to assess safety and pharmacokinetics and to identify the dose and schedule for phase 2. In phase 2 (dose-expansion cohort), objectives included the assessment of the overall response (partial response or better), safety, and efficacy of mezigdomide plus dexamethasone at the dose and schedule determined in phase 1. RESULTS: In phase 1, a total of 77 patients were enrolled in the study. The most common dose-limiting toxic effects were neutropenia and febrile neutropenia. On the basis of the phase 1 findings, investigators determined the recommended phase 2 dose of mezigdomide to be 1.0 mg, given once daily in combination with dexamethasone for 21 days, followed by 7 days off, in each 28-day cycle. In phase 2, a total of 101 patients received the dose identified in phase 1 in the same schedule. All patients in the dose-expansion cohort had triple-class-refractory multiple myeloma, 30 patients (30%) had received previous anti-B-cell maturation antigen (anti-BCMA) therapy, and 40 (40%) had plasmacytomas. The most common adverse events, almost all of which proved to be reversible, included neutropenia (in 77% of the patients) and infection (in 65%; grade 3, 29%; grade 4, 6%). No unexpected toxic effects were encountered. An overall response occurred in 41% of the patients (95% confidence interval [CI], 31 to 51), the median duration of response was 7.6 months (95% CI, 5.4 to 9.5; data not mature), and the median progression-free survival was 4.4 months (95% CI, 3.0 to 5.5), with a median follow-up of 7.5 months (range, 0.5 to 21.9). CONCLUSIONS: The all-oral combination of mezigdomide plus dexamethasone showed promising efficacy in patients with heavily pretreated multiple myeloma, with treatment-related adverse events consisting mainly of myelotoxic effects. (Funded by Celgene, a Bristol-Myers Squibb Company; CC-92480-MM-001 ClinicalTrials.gov number, NCT03374085; EudraCT number, 2017-001236-19.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2303194

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 22

  1. 10.1200/EDBK_238527 · DOI
  2. 10.1097/HS9.0000000000000045 · DOI
  3. 10.1111/ejh.13046 · DOI
  4. 10.1038/s41375-019-0435-7 · DOI · Paper page
  5. 10.1080/10428194.2021.1913143 · DOI
  6. 10.2217/fon-2021-1090 · DOI
  7. 10.1016/S2352-3026(22)00290-3 · DOI · Paper page
  8. 10.1016/j.molimm.2011.03.006 · DOI · Paper page
  9. 10.1182/blood-2007-07-098202 · DOI · Paper page
  10. Wong L Jiménez Nuñez MD Bahlis NJ et al. Pharmacodynamic (PD) responses drive dose/schedule selection of CC-92480 a novel CELMoD agent in a phase 1 dose-escalation study in relapsed/refractory multiple myeloma (RRMM). J Clin Oncol 2020;38:Suppl:8531-8531. abstract (https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.8531). · DOI
  11. Wong L Narla RK Leisten J et al. CC-92480 a novel cereblon E3 ligase modulator is synergistic with dexamethasone bortezomib and daratumumab in multiple myeloma. Blood 2019;134:Suppl 1:1815-1815. abstract (https://ashpublications.org/blood/article/134/Supplement_1/1815/427718/CC-92480-a-Novel-Cereblon-E3-Ligase-Modulator-Is). · doi:10.1182/blood-2019-124345
  12. 10.1182/blood-2010-10-299487 · DOI · Paper page
  13. 10.1080/10543400902802409 · doi:10.1080/10543400902802409
  14. 10.1016/S1470-2045(13)70380-2 · DOI · Paper page
  15. 10.1007/s11899-020-00568-3 · DOI
  16. 10.3389/fimmu.2021.720571 · DOI
  17. 10.1016/j.clml.2015.07.641 · DOI
  18. 10.1182/blood-2016-01-631200 · DOI · Paper page
  19. 10.1634/theoncologist.2016-0104 · DOI · Paper page
  20. 10.1038/s41408-018-0141-0 · DOI · Paper page
  21. 10.1002/ajh.25134 · DOI
  22. Richardson PG Sandhu I Oriol A et al. Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk 2022;22:Suppl:S33-S33. abstract (https://www.clinical-lymphoma-myeloma-leukemia.com/article/S2152-2650(22)00326-3/fulltext). · doi:10.1016/s2152-2650(22)00326-3

Cited by

See all 102

Metadata

Authors
Richardson, P. G., Trudel, S., Popat, R., Mateos, M.-V., Vangsted, A. J., Ramasamy, K., Martinez-Lopez, J., Quach, H., Orlowski, R. Z., Arnao, M., Lonial, S., Karanes, C., Pawlyn, C., Kim, K., Oriol, A., Berdeja, J. G., Rodríguez Otero, P., Casas-Avilés, I., Spirli, A., Poon, J., Li, S., Gong, J., Wong, L., Lamba, M., Pierce, D. W., Amatangelo, M., Peluso, T., Maciag, P., Katz, J., Pourdehnad, M., & Bahlis, N. J.
Venue
New England Journal of Medicine
Published
2023-09-14
Volume
389
Issue
11
Pages
1009-1022
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W4386271388
Cited by
102
References
17
FWCI
18.00
Type
journal article
Language
en
Open access
green
Funders
Bristol-Myers Squibb

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. https://app.cochat.ai/papers/10.1056/nejmoa2303194
The paper
Richardson, P. G., Trudel, S., Popat, R., Mateos, M.-V., Vangsted, A. J., Ramasamy, K., Martinez-Lopez, J., Quach, H., Orlowski, R. Z., Arnao, M., Lonial, S., Karanes, C., Pawlyn, C., Kim, K., Oriol, A., Berdeja, J. G., Rodríguez Otero, P., Casas-Avilés, I., Spirli, A., . . . Bahlis, N. J. (2023). Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2303194

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.